Imbruvica, Gazyva combo meets in first-line CLL

AbbVie Inc. (NYSE:ABBV) said Imbruvica ibrutinib plus Gazyva obinutuzumab met the primary endpoint of improving progression-free survival (PFS) in the Phase III iLLUMINATE (PCYC-1130) trial

Read the full 250 word article

User Sign In